Expansion into Europe for BlueRock Therapeutics
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has…
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has…
With many targeted protein degraders hitting the clinic, lucrative collaborations and acquisitions are being signed…
Until this year, there were no effective treatments for chronic kidney disease. However, the recent…
Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s…
Bayer and the French biotech company Meiogenix will work together to advance the development of…
Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly…
In 2016, German pharma giant Bayer took a bold step and decided to partner with…
Some careers take on an international scope and span the breadth of big players in…
Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer…
The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could…
Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for…
Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs…